Newly discovered immunohistochemical markers and micro-RNAs detected in testicular germ–cell tumors

##plugins.themes.bootstrap3.article.sidebar##

PDF
DOI: https://doi.org/10.30841/2307-5090.1(56).2016.95378
Keywords:
immunohistochemical markers, micro-RNA, germ–cell tumors,

##plugins.themes.bootstrap3.article.main##

А. В. Сакало
ГУ «Институт урологии НАМН Украины», Ukraine
П. Г. Яковлєв

Abstract

Testicular germ-cell tumors (TGCTs) are the most frequent malignant tumors in men 20–40 years of age and the most frequent cause of death in this age group. TGCTs consist of two major histological groups: seminomas and nonseminomatous germ-cell tumors (NSGCTs). NSGCTs can be further divided into embryonic carcinoma, teratoma, yolk sac tumor, and choriocarcinoma, which differ in therapy, prognosis, but all show characteristics of the primordial germ cells. New biomarkers – OCT3/4, SOX2, SOX17, HMGA1, Nek2, GPR30 – represent novel molecular targets for antineoplastic strategies. The role of micro-RNA is highlighted as molecular prognostic factor in patients with TGCT.

##plugins.themes.bootstrap3.article.details##

How to Cite
Сакало, А. В., & Яковлєв, П. Г. (2016). Newly discovered immunohistochemical markers and micro-RNAs detected in testicular germ–cell tumors. Health of Man, (1(56), 24–26. https://doi.org/10.30841/2307-5090.1(56).2016.95378
Issue
No. 1(56) (2016)
Section
Topical issues
Copyright (c) 2020 А. В. Сакало, П. Г. Яковлєв

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.

Author Biography

А. В. Сакало, ГУ «Институт урологии НАМН Украины»

Сакало Анатолий Валериевич

References

Gilligan TD. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors / TD. Gilligan, J. Seidenfeld, EM. Basch [et al.] // J.Clin.Oncol. 2010 Jul 10;28(20):3388–404.

Barlow L. Serum tumor markers in the evaluation of male germ cell tumors / L. Barlow, G. Badalato, J. McKiernan // Nat Rev Urol. 2010 Nov;7(11):610–7.

Krege S. The role of tumour markers in diagnosis and management of testicular germ cell tumours / S. Krege, P. Albers, A. Heidenreich // Urologe A. 2011 Mar;50(3):313–21.

Neumann A. Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer / A. Neumann, T. Keller, D. Jocham, C. Doehn // Aktuelle Urol. 2011 Sep;42(5):311–5.

Gilligan T. American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors / T.Gilligan, J. Seidenfeld, E.Basch [et al.] // J Clin Oncol. 2010 Jul 10;28(20):3388–404.

Syring I. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer / I. Syring, J. Bartels, S. Holdenrieder [et al.] // J Urol. 2015 Jan;193(1):331–7.

Ulbright TM. The most common, clinically significant misdiagnoses in testicular tumor pathology, and how to avoid them / TM. Ulbright // Adv Anat Pathol. 2008 Jan;15(1):18–27.

Cleynen I, The HMGA proteins: a myriad of functions (Review) / V. Cleynen, W. Van de Ven // Int J Oncol. 2008 Feb;32(2):289–305.

Pallante P. High mobility group a proteins as tumor markers / P. Pallant, R. Sepe, F. Puca, A. Fusco // Front Med. 2015 Mar 25;2:15.

Chieffi P. Recent advances in molecular and cell biology of testicular germcell tumors / P. Chieffi // Int Rev Cell Mol Biol. 2014;312:79–100.

Chieffi P. An update on newly discovered immunohistochemical biomarkers for the diagnosis of human testicular germ cell tumors / P. Chieffi, S. Chieffi // Histol Histopathol. 2014 Aug;29(8).

Barbagallo F, Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas / F. Barbagallo, M. Paronetto, R. Franco [et al.] //J Pathol. 2009 Feb;217(3):431–41.

Naro C. The centrosomal kinase NEK2 is a novel splicing factor kinase involved in cell survival / C. Naro, F. Barbagallo, Chieffi [et al.] // Nucleic Acids Res. 2014; 42, 3218–3227.

Looijenga L. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors / L. Looijenga, H. Stoop, H.de Leeuw [et al.] // Cancer Res. 2003 May 1; 63(9):2244–50.

Gillis A. Expression and interdependencies of pluripotency factors LIN28, OCT3/4, NANOG and SOX2 in human testicular germ cells and tumours of the testis / A. Gillis, H. Stoop, K. Biermann [et al.] // Int J Androl. 2011 Aug;34(4 Pt 2):e160–74.

Dieckmann K, MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours / K. Dieckmann, M. Spiekermann, T. Balks [et al.] // Br J Cancer. 2012 Nov 6;107(10):1754–60.

Spiekermann M. MicroRNA miR371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker / M. Spiekermann, G. Belge, N. Winter [et al.] // Andrology. 2015 Jan;3(1):78–84.

Rounge T. Profiling of the small RNA populations in human testicular germ cell tumors shows global loss of piRNAs / T. Rounge, K. Furu, R. Skotheim [et al.] // Mol Cancer. 2015 Aug 12;14:153.

Spiekermann M. Is relative quantification dispensable for the measurement of microRNAs as serum biomarkers in germ cell tumors? / M.Spiekermann, K. Dieckmann, T.Balks [et al.] // Anticancer Res. 2015 Jan;35(1):117–21.

Syring I. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer / I.Syring, J.Bartels, S. Holdenrieder [et al.] // J Urol. 2015 Jan;193(1):331–7.

Rijlaarsdam M, Identification of known and novel germ cell cancer-specific (embryonic) miRs in serum by highthroughput profiling / M. Rijlaarsdam, T. van Agthoven, A. Gillis [et al.] // Andrology. 2015 Jan;3(1):85–91.

Carthew R, Origins and Mechanisms of miRNAs and siRNAs / R. Carthew, E. Sontheimer // Cell. 2009 Feb 20;136(4):642–55.

Farazi T. MiRNAs in human cancer / T. Farazi, J. Spitzer, P. Morozov, T. Tuschl // J Pathol. 2011 Jan;223(2):102–15.

Bartel D. MicroRNAs: genomics, biogenesis, mechanism, and function / D. Bartel // Cell. 2004 Jan 23;116(2):281–97.

Esquela-Kerscher A. Oncomirs microRNAs with a role in cancer / A. Esquela-Kerscher, F. Slack // Nat Rev Cancer. 2006 Apr;6(4):259–69.

Farazi TA. miRNAs in human cancer / TA. Farazi, JI. Spitzer, P. Morozov, T. Tuschl // J Pathol. 2011, 223, 102–115.

Catto J. MicroRNA in prostate, bladder, and kidney cancer: a systematic review / J. Catto, A. Alcaraz, А. Bjartell [et al.] // Eur Urol. 2011 May;59(5):671–81.

Gillis A. High throughput microRNAome analysis in human germ cell tumors / A. Gillis Stopp H, R Hermus, J. Oosterhuis [et al.] // J Pathol. 2007, 213, 319–328.

Palmer R. Children’s Cancer and Leukaemia Group. Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets / R. Palmer, M. Murray, H. Saini [et al.] // Cancer Res. 2010 Apr 1;70(7):2911–23.

Gillis A. Targeted serum miRNA(TSmiR) test for diagnosis and follow-up of testicular germ cell cancer patients: a proof of principle / A.Gillis, M.Rijlaarsdam, R.Eini [et al.] // Mol Oncol. 2013 Dec;7(6):1083–92.

Ruf C. Small RNAs in the peripheral blood discriminate metastasized from non-metastasized seminoma / C. Ruf, D. Dinger, M. Port [et al.] // Mol Cancer. 2014 Mar 6;13:47.